Luis Alberto Marin Rubio
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Luis Alberto Marin Rubio has a total of 302 co-authors. Here are the top co-authors by number of shared publications:
- Jesus Ontañon
Immunology Unit, Clinical Analysis Department Albacete University Hospital Complex Albacete Spain
26 shared publications - Alfredo Minguela
Biomedical Research Institute of Murcia (IMIB), 30120 Murcia, Spain
12 shared publications Ramon Rada
Immunology Unit, Clinical Analysis Department Albacete University Hospital Complex Albacete Spain
10 shared publications- Ramón García-Sanz
Hematology Department Hospital General Universitario Gregorio Marañón Madrid Spain
10 shared publications Ana Balanzategui
Hematology Department, University Hospital of Salamanca and Research Biomedical Institute of Salamanca (IBSAL), Paseo de San Vicente, 58-182, 37007, Salamanca, Spain
9 shared publications- Maria Carmen Chillon
Hospital Universitario de Salamanca, IBSAL, CIBER-ONC number CB16/12/00233 y Centro de Investigacion del Cancer de Salamanca-IBMCC (USAL-CSIC), Salamanca, Salamanca, Spain
9 shared publications
Latest Publications
Characterisation of Two New Alleles, HLA‐C*03:02:02:19 and ‐DQB1*06:09:01:04 , in a Spanish Bone Marrow Donor
Genomic sequences of the intronic variants HLA‐C*03:02:02:19 and ‐DQB1*06:09:01:04 .
Characterisation of Two New Alleles, HLA‐C*03:02:02:19 and ‐DQB1*06:09:01:04 , in a Spanish Bone Marrow Donor
Genomic sequences of the intronic variants HLA‐C*03:02:02:19 and ‐DQB1*06:09:01:04 .
Six Novel HLA‐DQB1*05 Intronic Variants Identified by Next‐Generation Sequencing
Genomic sequences of the intronic variants HLA‐DQB1*05:01:01:35 , ‐DQB1*05:01:01:36 , ‐DQB1*05:01:01:41 , ‐DQB1*05:02:01:20 , ‐DQB1*05:03:01:11 and ‐DQB1*05:03:01:13 .
Six Novel HLA‐DQB1*05 Intronic Variants Identified by Next‐Generation Sequencing
Genomic sequences of the intronic variants HLA‐DQB1*05:01:01:35 , ‐DQB1*05:01:01:36 , ‐DQB1*05:01:01:41 , ‐DQB1*05:02:01:20 , ‐DQB1*05:03:01:11 and ‐DQB1*05:03:01:13 .
- 29 April 2026
- Published by Wiley in British Journal of Haematology
- Vol. 208 (6) , 2175-2184
HLA profile in paediatric ITP : Comparison with healthy controls and prognostic implications
Summary: Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by isolated low platelet counts. Although several studies have explored the relationship between the human leucocyte antigen (HLA) system and ITP, findings have been inconsistent. We compared HLA typing between paediatric ITP patients and healthy controls to assess its role in ITP susceptibility. We also evaluated the association between HLA alleles and clinical outcomes in our paediatric ITP cohort. This retrospective observational study included 135 patients with primary ITP and a control group of 929 healthy individuals. The median age of ITP patients was 5.71 years (Interquartile range 2.71–10.21). The HLA‐DRB1*07 and HLA‐DRB1*13 alleles were more prevalent in healthy controls than in ITP patients, suggesting a potential protective role ( p < 0.05). In contrast, HLA‐A*68, HLA‐B*40 and HLA‐DRB1*14 alleles were associated with an increased risk of ITP ( p < 0.05). Regarding prognosis, HLA‐A*26 allele correlated with lower recovery rates, while HLA‐C*03 allele was associated with a higher recovery likelihood ( p < 0.05). In addition, HLA‐A*02 and HLA‐C*04 alleles and the HLA‐A02 supertype showed a significant association with a higher probability of chronicity ( p < 0.05). Our results highlight the potential role of HLA typing as a diagnostic and prognostic tool for ITP. However, larger studies are required to validate these associations.
- 29 April 2026
- Published by Wiley in British Journal of Haematology
- Vol. 208 (6) , 2175-2184
HLA profile in paediatric ITP : Comparison with healthy controls and prognostic implications
Summary: Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by isolated low platelet counts. Although several studies have explored the relationship between the human leucocyte antigen (HLA) system and ITP, findings have been inconsistent. We compared HLA typing between paediatric ITP patients and healthy controls to assess its role in ITP susceptibility. We also evaluated the association between HLA alleles and clinical outcomes in our paediatric ITP cohort. This retrospective observational study included 135 patients with primary ITP and a control group of 929 healthy individuals. The median age of ITP patients was 5.71 years (Interquartile range 2.71–10.21). The HLA‐DRB1*07 and HLA‐DRB1*13 alleles were more prevalent in healthy controls than in ITP patients, suggesting a potential protective role ( p < 0.05). In contrast, HLA‐A*68, HLA‐B*40 and HLA‐DRB1*14 alleles were associated with an increased risk of ITP ( p < 0.05). Regarding prognosis, HLA‐A*26 allele correlated with lower recovery rates, while HLA‐C*03 allele was associated with a higher recovery likelihood ( p < 0.05). In addition, HLA‐A*02 and HLA‐C*04 alleles and the HLA‐A02 supertype showed a significant association with a higher probability of chronicity ( p < 0.05). Our results highlight the potential role of HLA typing as a diagnostic and prognostic tool for ITP. However, larger studies are required to validate these associations.
HLA‐DPA1*01:228 is the First DPA1 Allele Described With an Alanine at Position 42 of Alpha‐1 Domain
HLA‐DPA1*01:228 shows an alanine at position 42 not described previously.
HLA‐DPA1*01:228 is the First DPA1 Allele Described With an Alanine at Position 42 of Alpha‐1 Domain
HLA‐DPA1*01:228 shows an alanine at position 42 not described previously.
Genomic Sequence of Six New Variants of HLA‐DQB1*06
Genomic sequences of the HLA‐DQB1*06:02:01:38, ‐DQB1*06:02:01:39, ‐DQB1*06:03:01:25, ‐DQB1*06:03:01:27, ‐DQB1*06:04:01:09 and ‐DQB1*06:529 alleles.
Genomic Sequence of Six New Variants of HLA‐DQB1*06
Genomic sequences of the HLA‐DQB1*06:02:01:38, ‐DQB1*06:02:01:39, ‐DQB1*06:03:01:25, ‐DQB1*06:03:01:27, ‐DQB1*06:04:01:09 and ‐DQB1*06:529 alleles.
Four Novel Intronic Variants of HLA‐B Identified by Next‐Generation Sequencing
Characterisation of the HLA‐B*07:02:01:131, ‐B*35:08:01:14, ‐B*44:02:01:88 and ‐B*44:03:01:76 alleles in Spanish individuals.
Four Novel Intronic Variants of HLA‐B Identified by Next‐Generation Sequencing
Characterisation of the HLA‐B*07:02:01:131, ‐B*35:08:01:14, ‐B*44:02:01:88 and ‐B*44:03:01:76 alleles in Spanish individuals.
NK Alloreactivity Evaluation According to KIR‐HLA Interaction Models Influences the Outcome of Haploidentical Haematopoietic Stem‐Cell Transplantation Based on Post‐Transplant Cyclophosphamide
Haploidentical haematopoietic stem‐cell transplantation (haplo‐HSCT) is characterised by a high degree of HLA mismatching. Therefore, NK alloreactivity driven by the interactions between KIR and HLA mismatched molecules could benefit its outcome. However, the influence of NK alloreactivity in haplo‐HSCT with post‐transplant Cyclophosphamide (PTCy) remains controversial. The aim of this work was to investigate the clinical utility of predicting NK alloreactivity according to previously described models in the context of haplo‐HSCT with PTCy. We studied 145 patients who underwent this procedure, evaluating the influence of NK alloreactivity in transplant outcomes. Models that disregard the interactions between KIR and HLA evidenced an unsuccessful prediction of the outcomes. On the contrary, approaches based on KIR‐HLA interaction were the most accurate to predict transplant outcomes. The analysis of inhibitory KIRs (iKIRs) based on the missing‐ligand model showed that the presence of at least two iKIR mismatches (iKIRmm) among the donor‐recipient pair was an independent risk factor for acute graft‐versus‐host disease (aGvHD) grade III‑IV (HR: 3.21, p = 0.021), relapse rate (HR: 2.46, p = 0.046), relapse‐free survival (RFS) (HR: 1.96, p = 0.039) and GvHD/relapse‐free survival (GRFS) (HR = 2.16, p = 0.008). The analysis of the missing‐licensing model showed that the existence of the mismatch KIR2DL1/C2 associated to relapse rate (HR: 4.34, p = 0.002) and more than one iKIRmm correlated to poorer RFS (HR: 2.31, p = 0.038) and GRFS (HR: 2.26, p = 0.022). These results suggest that NK alloreactivity influences the outcome of haplo‐HSCT with PTCy and should be incorporated into the donor selection algorithm for this procedure.
NK Alloreactivity Evaluation According to KIR‐HLA Interaction Models Influences the Outcome of Haploidentical Haematopoietic Stem‐Cell Transplantation Based on Post‐Transplant Cyclophosphamide
Haploidentical haematopoietic stem‐cell transplantation (haplo‐HSCT) is characterised by a high degree of HLA mismatching. Therefore, NK alloreactivity driven by the interactions between KIR and HLA mismatched molecules could benefit its outcome. However, the influence of NK alloreactivity in haplo‐HSCT with post‐transplant Cyclophosphamide (PTCy) remains controversial. The aim of this work was to investigate the clinical utility of predicting NK alloreactivity according to previously described models in the context of haplo‐HSCT with PTCy. We studied 145 patients who underwent this procedure, evaluating the influence of NK alloreactivity in transplant outcomes. Models that disregard the interactions between KIR and HLA evidenced an unsuccessful prediction of the outcomes. On the contrary, approaches based on KIR‐HLA interaction were the most accurate to predict transplant outcomes. The analysis of inhibitory KIRs (iKIRs) based on the missing‐ligand model showed that the presence of at least two iKIR mismatches (iKIRmm) among the donor‐recipient pair was an independent risk factor for acute graft‐versus‐host disease (aGvHD) grade III‑IV (HR: 3.21, p = 0.021), relapse rate (HR: 2.46, p = 0.046), relapse‐free survival (RFS) (HR: 1.96, p = 0.039) and GvHD/relapse‐free survival (GRFS) (HR = 2.16, p = 0.008). The analysis of the missing‐licensing model showed that the existence of the mismatch KIR2DL1/C2 associated to relapse rate (HR: 4.34, p = 0.002) and more than one iKIRmm correlated to poorer RFS (HR: 2.31, p = 0.038) and GRFS (HR: 2.26, p = 0.022). These results suggest that NK alloreactivity influences the outcome of haplo‐HSCT with PTCy and should be incorporated into the donor selection algorithm for this procedure.
Genomic Sequence of Five New Intronic Variants of HLA‐DQB1*03 Characterised by Next‐Generation Sequencing
Genomic sequences of the HLA‐DQB1*03:01:01:70, ‐DQB1*03:01:01:77, ‐DQB1*03:02:01:28, ‐DQB1*03:02:01:29, and ‐DQB1*03:03:02:19 alleles.
Genomic Sequence of Five New Intronic Variants of HLA‐DQB1*03 Characterised by Next‐Generation Sequencing
Genomic sequences of the HLA‐DQB1*03:01:01:70, ‐DQB1*03:01:01:77, ‐DQB1*03:02:01:28, ‐DQB1*03:02:01:29, and ‐DQB1*03:03:02:19 alleles.
Frequency and Distribution of KIR Genotypes of Donors‐Recipient Pairs in the Haploidentical Haematopoietic Stem Cell Transplantation Setting: Collaborative Study by the Spanish Working Group in Histocompatibility and Transplant Immunology (GETHIT) and the Spanish Haematopoietic Transplantation and Cell Therapy Group (GETH‐TC)
There is limited information regarding the influence of KIR genotype, compared to the HLA system, in haploidentical haematopoietic stem cell transplantation (haplo‐HSCT). This study aimed to determine the frequencies of KIR genotypes in Spanish haematologic patients undergoing haplo‐HSCT. A study was conducted on 113 oncohaematological patients and their donors, treated across five centres that are members of the Spanish Working Group in Histocompatibility and Transplant Immunology (GETHIT) and the Spanish Haematopoietic Transplantation and Cell Therapy Group (GETH‐TC). KIR typing was performed using PCR‐rSSO or PCR‐SSP. KIR genotypes were identified using the KIR Allele Frequency Net Database. Among donors, the most frequent KIR genotypes were Type 1 (28.3%), Type 2 (12.4%) and Type 4 (10.6%). In patients, Genotypes 1 (23.9%), 4 (23%) and 2 (14.2%) were most prevalent. Donors exhibited AA centromeric (46%) and telomeric (59.3%) types, while patients had a higher AB centromeric frequency (52.2%). Differences were observed in the BB centromeric type (3.5% patients; 16.8% donors, p = 0.002). The AB KIR genotype was the most common (70.8% donors; 75.2% patients). Most were classified as ‘neutral’ (61.9% donors; 73.5% patients). B‐content score1 was the most common (48.7% patients; 33.6% donors). Notably, classification as best was rare (2.7% patients; 16.8% donors, p = 0.002). The study highlights the distribution of KIR genotypes in haplo‐HSCT patients and donors, with Genotypes 1, 2 and 4 being the most prevalent. AB KIR genotypes and B‐content score 1 were dominant. Moreover, KIR genotypes ID may serve as criteria for future investigation about the immunogenetic predisposition to malignant haematological diseases.
Frequency and Distribution of KIR Genotypes of Donors‐Recipient Pairs in the Haploidentical Haematopoietic Stem Cell Transplantation Setting: Collaborative Study by the Spanish Working Group in Histocompatibility and Transplant Immunology (GETHIT) and the Spanish Haematopoietic Transplantation and Cell Therapy Group (GETH‐TC)
There is limited information regarding the influence of KIR genotype, compared to the HLA system, in haploidentical haematopoietic stem cell transplantation (haplo‐HSCT). This study aimed to determine the frequencies of KIR genotypes in Spanish haematologic patients undergoing haplo‐HSCT. A study was conducted on 113 oncohaematological patients and their donors, treated across five centres that are members of the Spanish Working Group in Histocompatibility and Transplant Immunology (GETHIT) and the Spanish Haematopoietic Transplantation and Cell Therapy Group (GETH‐TC). KIR typing was performed using PCR‐rSSO or PCR‐SSP. KIR genotypes were identified using the KIR Allele Frequency Net Database. Among donors, the most frequent KIR genotypes were Type 1 (28.3%), Type 2 (12.4%) and Type 4 (10.6%). In patients, Genotypes 1 (23.9%), 4 (23%) and 2 (14.2%) were most prevalent. Donors exhibited AA centromeric (46%) and telomeric (59.3%) types, while patients had a higher AB centromeric frequency (52.2%). Differences were observed in the BB centromeric type (3.5% patients; 16.8% donors, p = 0.002). The AB KIR genotype was the most common (70.8% donors; 75.2% patients). Most were classified as ‘neutral’ (61.9% donors; 73.5% patients). B‐content score1 was the most common (48.7% patients; 33.6% donors). Notably, classification as best was rare (2.7% patients; 16.8% donors, p = 0.002). The study highlights the distribution of KIR genotypes in haplo‐HSCT patients and donors, with Genotypes 1, 2 and 4 being the most prevalent. AB KIR genotypes and B‐content score 1 were dominant. Moreover, KIR genotypes ID may serve as criteria for future investigation about the immunogenetic predisposition to malignant haematological diseases.
Two New Alleles, HLA ‐B*40:06:01:20 and HLA ‐ DRB1 *09: 61N , Detected in a Spanish Bone Marrow Donor
Genomic sequence of HLA‐B*40:06:01:20 and HLA‐DRB1*09:61N alleles detected in a Spanish individual.
Two New Alleles, HLA ‐B*40:06:01:20 and HLA ‐ DRB1 *09: 61N , Detected in a Spanish Bone Marrow Donor
Genomic sequence of HLA‐B*40:06:01:20 and HLA‐DRB1*09:61N alleles detected in a Spanish individual.